Merck will continue development of KalVista Pharmaceuticals’ investigative diabetic macular edema drug KVD001, according to a KalVista press release.
Merck will receive certain rights, including an option to acquire intravitreal KVD001 after a phase 2 proof-of-concept trial, under the terms of the agreement. KalVista will also grant Merck similar options for investigational orally delivered molecules for DME that KalVista will continue to develop, the release said.
Merck will pay a $37 million upfront fee, and KalVista will be eligible to receive payments up to $715 million depending on
Uncategorized